BIO bio-rad.com: Business Value to Revenue

Official company branding of Bio-Rad (BIO)

Bio-Rad Laboratories generates revenue through the sale of diagnostic test systems and laboratory equipment. The company's enterprise value-to-revenue ratio reflects the business valuation trend, with 3714.42 representing the current level of this metric. A stable staff of scientists ensures the retention of core competencies, yet fierce competition for healthcare facility budgets forces the company to continuously invest in innovative developments.

BIO bio-rad.com EV/Sales Multiple (11/23/2025 - 11/20/2026)

BIO (Bio-Rad Laboratories Inc): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- company stock capitalization data:
Fundamental company valuation:BIO - Bio-Rad Laboratories
Product sample of Bio-Rad Laboratories, Inc.

The EV/Sales multiple determines the enterprise value of the business, including net debt, relative to generated sales volume, allowing for an assessment of operational efficiency regardless of financial leverage. By analyzing the EV/Sales multiple, an investor identifies risks of revenue stagnation for Bio-Rad Laboratories (BIO), which requires the Schwartz family to confirm their ability to restore organic growth and execute a high-quality M&A strategy.

Competitor analysis for Bio-Rad Laboratories

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|Company Value to Revenue NNNN (Anbio Biotechnology)|SHC (Sotera Health Company) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio QuidelOrtho Inc. QDEL|EV/Sales Multiple OPKO Health Inc OPK|CareDx Inc - EV/Sales Multiple|Business Value to Revenue MRVI (Maravai)|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue